Invitae Common Hereditary Cancers Panel
Use
The Invitae Common Hereditary Cancers Panel analyzes genes associated primarily with adult-onset, nonsyndromic predisposition to cancers of the breast, ovary, uterus, prostate, and gastrointestinal system. This test is designed for heritable germline mutations and is not suitable for detecting somatic mutations in tumor tissue. It provides comprehensive analysis to help confirm clinical diagnoses, predict disease prognosis and progression, facilitate early symptom detection, inform family planning, and aid in genetic counseling.
Special Instructions
This panel covers 48 genes and is designed for germline mutation detection in blood, saliva, buccal swab, or genomic DNA. It is not suitable for analyzing somatic mutations in tumors.
Limitations
The test achieves >99% analytical sensitivity and specificity for detecting single nucleotide variants, insertions, deletions <15bp, and exon-level deletions and duplications. Large insertions and deletions larger than 15bp but smaller than a full exon may have reduced sensitivity. Structural rearrangements, complex sequence variants, and single-exon copy number events may not be detected. Variants in the promoter, non-coding exons, and other non-coding regions are not typically covered.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
10-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
3mL
Minimum Volume
Not provided
Container
purple-top EDTA tube (K2EDTA or K3EDTA)
Other tests from different labs that may be relevant